Salazar-Orellana Jaime L I, García-Grimshaw Miguel, Valdés-Ferrer Sergio I, Alday-Ramírez Sergio M, Ríos-Argaiz Eduardo, Vásquez-Ortiz Zuilma Y, Rivero-Sigarroa Eduardo, Jiménez-Ruiz Amado, Chiquete Erwin, Cantú-Brito Carlos, Flores-Silva Fernando D
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMyNSZ), Mexico City, Mexico.
Department of Neurology and Psychiatry, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMyNSZ), Mexico City, Mexico; Center for Biomedical Science, Feinstein Institute for Medical Research, Manhasset, New York, USA.
Rev Invest Clin. 2021 Jan 11;73(2):61-64. doi: 10.24875/RIC.20000569.
In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated disease coronavirus disease 2019 (COVID-19), hypoxemia mechanisms differ from those observed in acute respiratory distress syndrome. Hypoxemia and respiratory failure in COVID- 19 are attributed to pulmonary angiopathy, increasing physiological pulmonary shunting1-3.
在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关疾病冠状病毒病2019（COVID-19）中，低氧血症机制与急性呼吸窘迫综合征中观察到的机制不同。COVID-19中的低氧血症和呼吸衰竭归因于肺血管病变，导致生理性肺内分流增加1-3。
